References

Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume

10.1016/j.euf.2023.03.024 · 2023 · External reference

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

10.1016/s0140-6736(22)00367-1 · 2022 · External reference

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

10.1056/nejmoa2119115 · 2022 · External reference

Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial

10.1200/jco.23.00041 · 2023 · External reference

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

10.1038/s43018-023-00692-y · 2024 · External reference

Triplet therapy for metastatic castration-sensitive prostate cancer: rationale and clinical evidence

10.1111/iju.15647 · 2025 · External reference

Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis

10.1016/j.eururo.2022.08.002 · 2022 · External reference

First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis

10.1001/jamaoncol.2022.7762 · 2023 · External reference

An updated systematic review and network meta-analysis of first-line triplet vs. doublet therapies for metastatic hormone-sensitive prostate cancer

10.3390/cancers17020205 · 2025 · External reference

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: phase 3 ARASENS subgroup analysis

10.1002/cam4.70029 · 2024 · External reference

Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study

10.1093/jjco/hyae098 · 2024 · External reference

Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

10.1016/j.prnil.2024.11.003 · 2025 · External reference

Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study

10.1007/s11255-025-04465-7 · 2025 · External reference

Preliminary report on the efficacy and safety of triplet therapy in patients with metastatic hormone-sensitive prostate cancer: YUSHIMA study

10.1111/iju.70154 · 2025 · External reference

Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an Austrian multicenter study

10.1016/j.clgc.2023.12.018 · 2024 · External reference

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer

10.1056/nejmoa1503747 · 2015 · External reference

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

10.1056/nejmoa1704174 · 2017 · External reference

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

10.1016/j.annonc.2023.02.009 · 2023 · External reference

Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study

10.1016/j.eururo.2024.03.036 · 2024 · External reference

Therapy optimization in the management of metastatic hormone-sensitive prostate cancer: insights from the ARASENS study

10.1016/j.eururo.2024.05.010 · 2024 · External reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

10.1056/nejmoa040720 · 2004 · External reference